TY - JOUR
T1 - Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes
AU - Heise, Tim
AU - DeVries, J. Hans
AU - Urva, Shweta
AU - Li, Jing
AU - Pratt, Edward J.
AU - Thomas, Melissa K.
AU - Mather, Kieren J.
AU - Karanikas, Chrisanthi A.
AU - Dunn, Julia
AU - Haupt, Axel
AU - Milicevic, Zvonko
AU - Coskun, Tamer
N1 - Publisher Copyright: © 2023 by the American Diabetes Association.
PY - 2023/5/1
Y1 - 2023/5/1
N2 - OBJECTIVE: To evaluate the effects of tirzepatide on body composition, appetite, and energy intake to address the potential mechanisms involved in body weight loss with tirzepatide. RESEARCH DESIGN AND METHODS: In a secondary analysis of a randomized, double-blind, parallel-arm study, the effects of tirzepatide 15 mg (N = 45), semaglutide 1 mg (N = 44), and placebo (N = 28) on body weight and composition, appetite, and energy intake were assessed at baseline and week 28. RESULTS: Tirzepatide treatment demonstrated significant reductions in body weight compared with placebo and semaglutide, resulting in greater fat mass reduction. Tirzepatide and semaglutide significantly reduced appetite versus placebo. Appetite scores and energy intake reductions did not differ between tirzepatide and semaglutide. CONCLUSIONS: Differences in energy intake during ad libitum lunch were not sufficient to explain the different weight outcomes. Further evaluation is needed to assess mechanistic differences related to tirzepatide actions on 24-h energy intake, substrate utilization, and energy expenditure.
AB - OBJECTIVE: To evaluate the effects of tirzepatide on body composition, appetite, and energy intake to address the potential mechanisms involved in body weight loss with tirzepatide. RESEARCH DESIGN AND METHODS: In a secondary analysis of a randomized, double-blind, parallel-arm study, the effects of tirzepatide 15 mg (N = 45), semaglutide 1 mg (N = 44), and placebo (N = 28) on body weight and composition, appetite, and energy intake were assessed at baseline and week 28. RESULTS: Tirzepatide treatment demonstrated significant reductions in body weight compared with placebo and semaglutide, resulting in greater fat mass reduction. Tirzepatide and semaglutide significantly reduced appetite versus placebo. Appetite scores and energy intake reductions did not differ between tirzepatide and semaglutide. CONCLUSIONS: Differences in energy intake during ad libitum lunch were not sufficient to explain the different weight outcomes. Further evaluation is needed to assess mechanistic differences related to tirzepatide actions on 24-h energy intake, substrate utilization, and energy expenditure.
UR - http://www.scopus.com/inward/record.url?scp=85159735776&partnerID=8YFLogxK
U2 - https://doi.org/10.2337/dc22-1710
DO - https://doi.org/10.2337/dc22-1710
M3 - Article
C2 - 36857477
SN - 0149-5992
VL - 46
SP - 998
EP - 1004
JO - Diabetes Care
JF - Diabetes Care
IS - 5
ER -